Phathom Pharmaceuticals Inc (PHAT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Phathom Pharmaceuticals Inc (PHAT) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.12 Million) by net assets ($-422.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PHAT market cap overview for the company's overall valuation and market capitalisation.
Phathom Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Phathom Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Phathom Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phathom Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See how well can Phathom Pharmaceuticals Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Alcha Aluminium Co Ltd
SHE:002160
|
-0.028x |
|
WhiteHawk Minerals Corp.
NYSE:WHK
|
0.007x |
|
Kimball Electronics
NASDAQ:KE
|
0.012x |
|
Nuveen Churchill Direct Lending Corp.
NYSE:NCDL
|
0.008x |
|
uPI Semiconductor Corp
TW:6719
|
0.020x |
|
Shanghai Sinotec Co Ltd
SHG:603121
|
0.048x |
|
Chatham Lodging Trust REIT
NYSE:CLDT
|
0.034x |
|
Donegal Group A Inc
NASDAQ:DGICA
|
0.009x |
Annual Cash Flow Conversion Efficiency for Phathom Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Phathom Pharmaceuticals Inc from 2018 to 2024. View today's stock price for Phathom Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.58 Million | $-266.77 Million | 1.052x | -44.36% |
| 2023-12-31 | $-72.76 Million | $-137.58 Million | 1.891x | -3.46% |
| 2022-12-31 | $-74.81 Million | $-146.53 Million | 1.959x | +195.20% |
| 2021-12-31 | $72.16 Million | $-148.46 Million | -2.057x | -473.56% |
| 2020-12-31 | $194.27 Million | $-69.69 Million | -0.359x | -123.97% |
| 2019-12-31 | $227.96 Million | $-36.51 Million | -0.160x | -120.13% |
| 2018-12-31 | $-1.29 Million | $-1.02 Million | 0.795x | -- |
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t… Read more